Patrick Shramm

Background

About Patrick Shramm

As the Director of Business Development at Advanced Targeting Systems (ATS), I lead the production and management of a diverse portfolio of research reagents used by scientists globally. My expertise encompasses the conjugation of proteins, peptides, and antibodies to various tags and payloads, as well as overseeing the complete product development lifecycle from initial concept and design through molecular cloning, production, purification, and testing. I have successfully developed and produced recombinant proteins across multiple species and systems, and I manage contract research services specializing in cell-based assays, including ELISA, cytotoxicity, receptor binding, flow cytometry, and drug screening. By collaborating closely with customers, I ensure that projects are tailored to meet their specific research needs and objectives. Supported by the SBIR program and NIH funding, I played a pivotal role in advancing one of our targeted toxins into human clinical trials for the treatment of cancer pain in opioid-resistant patients. I was involved in quality control assays, test material production, and stability testing throughout the clinical process. Additionally, I led an SBIR-funded initiative to enhance the specificity and delivery mechanisms of CRISPR gene-editing technology. Currently, I am assisting with the build-out of a CDMO facility, ensuring compliance with GMP standards to support drug manufacturing. In parallel with my responsibilities at ATS, I am pursuing an MBA at UC San Diego’s Rady School of Management to further develop my skills in business strategy, finance, operations, and leadership. Outside of work, I relish the opportunity to spend time outdoors with my dog, friends, and family. A memorable adventure was my five-month journey backpacking the entire Pacific Crest Trail. In my free time, I love traveling and pursuing various hobbies, including tennis, backpacking, biking, and ceramics.